|
WO2021026066A1
|
|
Compositions of trofinetide
|
|
WO2021080646A1
|
|
Bicyclic compounds and methods for their use in treating pitt hopkins syndrome
|
|
US2015224164A1
|
|
Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
|
|
EP3024463A2
|
|
Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
|
|
US2014309230A1
|
|
Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals
|
|
CA2929286A1
|
|
Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
|
|
WO2012150869A1
|
|
Antibodies that bind trefoil factors and methods of using same
|
|
AU2012209466A1
|
|
Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid
|
|
WO2011037644A1
|
|
Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
|
|
US2009304700A1
|
|
Conformation specific antibodies that bind trefoil factors
|
|
WO2009051844A1
|
|
Synthetic analogues of neural regeneration peptides
|
|
US2008145335A1
|
|
Analogs of glycyl-prolyl-glutamate
|
|
CN101743476A
|
|
Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same
|
|
EP2001400A2
|
|
Oral formulations of glycyl-2-methylprolyl-glutamate
|
|
WO2007119178A2
|
|
Infusion pump
|
|
US2007015707A1
|
|
Neuroprotective effect of activin in animals exposed to hypoxia/ischemia
|
|
WO2007011595A2
|
|
Neural regeneration peptides and antioxidants protect neurons from degeneration
|
|
EP1888618A2
|
|
Analogs of glycyl-prolyl-glutamate
|
|
US2006251649A1
|
|
Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
|
|
US2007004641A1
|
|
Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
|
